Your browser doesn't support javascript.
loading
Psychosocial Impact of Predictive Genetic Testing in Hereditary Heart Diseases: The PREDICT Study.
Bordet, Céline; Brice, Sandrine; Maupain, Carole; Gandjbakhch, Estelle; Isidor, Bertrand; Palmyre, Aurélien; Moerman, Alexandre; Toutain, Annick; Akloul, Linda; Brehin, Anne-Claire; Sawka, Caroline; Rooryck-Thambo, Caroline; Schaefer, Elise; Nguyen, Karine; Dupin Deguine, Delphine; Rouzier, Cécile; Billy, Gipsy; Séné, Krystelle; Denjoy, Isabelle; Leheup, Bruno; Planes, Marc; Mazzella, Jean-Michael; Staraci, Stéphanie; Hebert, Mélanie; Le Boette, Elsa; Michon, Claire-Cécile; Babonneau, Marie-Lise; Curjol, Angélique; Bekhechi, Amine; Mansouri, Rafik; Raji, Ibticem; Pruny, Jean-François; Fressart, Véronique; Ader, Flavie; Richard, Pascale; Tezenas du Montcel, Sophie; Gargiulo, Marcela; Charron, Philippe.
Afiliación
  • Bordet C; APHP, Referral Center for hereditary heart disease, Department of Genetics, Pitié-Salpêtrière University Hospital, 75013 Paris, France.
  • Brice S; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, F75013 Paris, France.
  • Maupain C; APHP, Referral Center for hereditary heart disease, Department of Genetics, Pitié-Salpêtrière University Hospital, 75013 Paris, France.
  • Gandjbakhch E; APHP, department of cardiology, Pitié-Salpêtrière University Hospital, 75013 Paris, France.
  • Isidor B; ACTION Study Group, Pitié-Salpêtrière University Hospital, 75013 Paris, France.
  • Palmyre A; APHP, Referral Center for hereditary heart disease, Department of Genetics, Pitié-Salpêtrière University Hospital, 75013 Paris, France.
  • Moerman A; APHP, department of cardiology, Pitié-Salpêtrière University Hospital, 75013 Paris, France.
  • Toutain A; ACTION Study Group, Pitié-Salpêtrière University Hospital, 75013 Paris, France.
  • Akloul L; Sorbonne Université, INSERM, UMRS 1166 and ICAN Institute for Cardiometabolism and Nutrition, 75013 Paris, France.
  • Brehin AC; Department of Genetics, Nantes University Hospital, 44000 Nantes, France.
  • Sawka C; APHP, department of Genetics, Ambroise Paré University Hospital, 92100 Boulogne-Billancourt, France.
  • Rooryck-Thambo C; Department of Genetics, Lille University Hospital, Jeanne de Flandre Hospital, 59000 Lille, France.
  • Schaefer E; Department of Medical Genetics, Tours University Hospital, 37044 Tours, France.
  • Nguyen K; Department of Medical Genetics, Rennes University Hospital, 35000 Rennes, France.
  • Dupin Deguine D; Normandie University, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics and Reference Center for Developmental Disorders, Normandy Center for Genomic and Personalized Medicine, F 76000, Rouen, France.
  • Rouzier C; Medical Genetics Unit, FHU TRANSLAD and GIMI Institute, Dijon University Hospital, 21000 Dijon, France.
  • Billy G; Department of Medical Genetics, CHU Bordeaux, Bordeaux, France, F-33000 Bordeaux, France.
  • Séné K; Department of Genetics, Strasbourg University Hospital, Institut de Génétique Médicale d'Alsace, 67200 Strasbourg, France.
  • Denjoy I; Department of Medical Genetics, APHM, Timone Hospital, Marseille Medical Genetics, Aix Marseille University, 13000 Marseille, France.
  • Leheup B; Department of Medical Genetics, Toulouse University Hospital, 31300 Toulouse, France.
  • Planes M; Department of Medical Genetics, Université Côte d'Azur, CHU, Inserm, CNRS, IRCAN, 06000 Nice, France.
  • Mazzella JM; Department of Medical Genetics, Centre Hospitalo-Universitaire Grenoble Alpes, 38700 Grenoble, France.
  • Staraci S; Clinical Genetics Unit, University Hospital, Guadeloupe University Hospital, 97159 Guadalupe Island, France.
  • Hebert M; APHP, Department of cardiology, Referral Center for hereditary heart disease, Bichat Hospital, 75018 Paris, France.
  • Le Boette E; Department of Medical Genetics, University Hospital, 54042 Nancy, France.
  • Michon CC; Department of Medical Genetics, University Hospital Morvan, 29200 Brest, France.
  • Babonneau ML; APHP, Department of Medical Genetics, Hôpital Européen Georges Pompidou,75015 Paris, France.
  • Curjol A; APHP, Referral Center for hereditary heart disease, Department of Genetics, Pitié-Salpêtrière University Hospital, 75013 Paris, France.
  • Bekhechi A; APHP, Referral Center for hereditary heart disease, Department of Genetics, Pitié-Salpêtrière University Hospital, 75013 Paris, France.
  • Mansouri R; Department of Genetics, Saint Brieuc Hospital, 22000 Saint-Brieuc, France.
  • Raji I; Filière nationale de santé CARDIOGEN, Pitié-Salpêtrière University Hospital, 75013 Paris, France.
  • Pruny JF; Filière nationale de santé CARDIOGEN, Pitié-Salpêtrière University Hospital, 75013 Paris, France.
  • Fressart V; APHP, Referral Center for hereditary heart disease, Department of Genetics, Pitié-Salpêtrière University Hospital, 75013 Paris, France.
  • Ader F; APHP, Referral Center for hereditary heart disease, Department of Genetics, Pitié-Salpêtrière University Hospital, 75013 Paris, France.
  • Richard P; APHP, Referral Center for hereditary heart disease, Department of Genetics, Pitié-Salpêtrière University Hospital, 75013 Paris, France.
  • Tezenas du Montcel S; APHP, Referral Center for hereditary heart disease, Department of Genetics, Pitié-Salpêtrière University Hospital, 75013 Paris, France.
  • Gargiulo M; APHP, Referral Center for hereditary heart disease, Department of Genetics, Pitié-Salpêtrière University Hospital, 75013 Paris, France.
  • Charron P; APHP, Department of cardiology, Referral Center for hereditary heart disease, Bichat Hospital, 75018 Paris, France.
J Clin Med ; 9(5)2020 May 06.
Article en En | MEDLINE | ID: mdl-32384747
ABSTRACT
Predictive genetic testing (PGT) is offered to asymptomatic relatives at risk of hereditary heart disease, but the impact of result disclosure has been little studied. We evaluated the psychosocial impacts of PGT in hereditary heart disease, using self-report questionnaires (including the State-Trait Anxiety Inventory) in 517 adults, administered three times to the prospective cohort (PCo n = 264) and once to the retrospective cohort (RCo n = 253). The main motivations for undergoing PGT were "to remove doubt" and "for their children". The level of anxiety increased between pre-test and result appointments (p <0.0001), returned to baseline after the result (PCo), and was moderately elevated at 4.4 years (RCo). Subjects with a history of depression or with high baseline anxiety were more likely to develop anxiety after PGT result (p = 0.004 and p <0.0001, respectively), whatever it was. Unfavourable changes in professional and/or family life were observed in 12.4% (PCo) and 18.7% (RCo) of subjects. Few regrets about PGT were expressed (0.8% RCo, 2.3% PCo). Medical benefit was not the main motivation, which emphasises the role of pre/post-test counselling. When PGT was performed by expert teams, the negative impact was modest, but careful management is required in specific categories of subjects, whatever the genetic test result.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Clin Med Año: 2020 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Clin Med Año: 2020 Tipo del documento: Article País de afiliación: Francia